
B-MOGEN Biotechnologies Inc Profile last edited on: 9/13/2019
CAGE: 7FUW2
UEI: LWAMX8BLAA85
Business Identifier: Custom tools for gene delivery and gene editing Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
1621 East Hennepin Avenue Suite B-15
Minneapolis, MN 55414
Minneapolis, MN 55414
(612) 309-7653 |
info@bmogen.com |
www.bmogen.com |
Location: Single
Congr. District: 05
County: Hennepin
Congr. District: 05
County: Hennepin
Public Profile
In June 2019 it was announced that Bio-Techne Corporation (NASDAQ: TECH) - with a track record of several small firm acquisitions - had reached agreement to acquire all of the stock of B-MoGen Biotechnologies Inc . B-Mogen is a four-year old University of Minnesota genome engineering startup start-up already having grown to some 20 employees. Working on the most complex gene editing problems with proprietary, cutting edge gene editing and delivery tools, B-Mogen is enabling and accelerating growth in immunotherapy treatments utilizing cutting edge gene editing and gene delivery technologies to create unique research solutions and disease models in human cell. The firm has several SBIR awards already taken and underway and has entered into strategic partnerships with biotechnology companies, completed projects for clients in academia and industry, along with having successfully licensed and developed novel intellectual property focused on genome engineering.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
20-24Revenue Range
2M-2.5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
10-14Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2020 | 2 | NIH | $1,624,672 | |
Project Title: Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy | ||||
2018 | 1 | NIH | $224,856 | |
Project Title: Development of Mitochondrial Disease Mouse Models | ||||
2017 | 1 | DARPA | $149,431 | |
Project Title: Next Generation Genome Editing Tools | ||||
2017 | 1 | NIH | $224,564 | |
Project Title: Effective engineering of the mitochondrial genome | ||||
2017 | 1 | NIH | $224,634 | |
Project Title: Stable Gene Transfer by RNA Delivery |
Key People / Management
Jeff Liter -- President and CEO
Anindya Bagchi -- Founder
Lampi Hermanson
Leah Hogdal
David L Lampi Hermanson
Branden S Moriarity -- Chief Scientific Officer
Neil Otto
Kristin Taylor Geisler -- Chief Financial Officer
Beau R Webber -- Director of Stem Cell Technologies
Anindya Bagchi -- Founder
Lampi Hermanson
Leah Hogdal
David L Lampi Hermanson
Branden S Moriarity -- Chief Scientific Officer
Neil Otto
Kristin Taylor Geisler -- Chief Financial Officer
Beau R Webber -- Director of Stem Cell Technologies
Company News
There are no news available.